As currently vascular endothelial growth factor (VEGF)-driven signaling remains predominant in tumor-related angiogenesis, this chapter focuses on this pathway and its specific inhibitors. In addition, for some other indications, such as renal cell carcinoma and hepatocellular carcinoma, the development of VEGF inhibiting agents has meant nothing less than a major breakthrough. With an ever increasing amount of clinical data and experience, it seems fair and safe to state that most VEGF inhibitors have shown an acceptable toxicity profile and thus can be considered to be by and large suitable for the general cancer patient population, including older persons. Important issues such as drug stability, plasma half-life, and biological availability are often addressed in preclinical/ADMET studies. The selection of inhibiting agents that will be developed further is largely dependent on the outcome of these studies.

, ,,
Department of Medical Oncology

Sie, M. P. S., & Eskens, F. (2014). Clinical Toxicity Profile of VEGF Inhibitors. doi:10.1002/9781118783344.ch24